Gain Therapeutics (NASDAQ:GANX) Posts Earnings Results, Meets Estimates

Gain Therapeutics (NASDAQ:GANX) issued its quarterly earnings results on Monday. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13), RTT News reports. During the same quarter in the prior year, the business posted ($0.16) earnings per share.

Gain Therapeutics Trading Up 0.3%

GANX traded up $0.01 during trading on Monday, hitting $1.83. 354,789 shares of the stock traded hands, compared to its average volume of 757,326. The firm has a market capitalization of $77.84 million, a P/E ratio of -2.99 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.63 and a quick ratio of 6.63. The firm has a 50-day moving average of $2.14 and a 200 day moving average of $2.39. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gain Therapeutics in a research note on Friday, April 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares during the period. Sprott Inc. purchased a new stake in shares of Gain Therapeutics in the 4th quarter worth about $39,000. Commonwealth Equity Services LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter worth about $41,000. Millennium Management LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter worth about $45,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Gain Therapeutics in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.